Clinical trial
A Study to Evaluate the Safety and Tolerability of Long-term Administration of…
NCT04339413 · Hoffmann-La Roche, Industry · Terminated
Key facts
| NCT number | NCT04339413 |
|---|---|
| Title | A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD) |
| Official title | An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's Disease |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | Gantenerumab |
| Enrollment | 116 |
| Start date | May 22, 2020 |
| Primary completion | Jan 4, 2023 |
| Completion | Jan 4, 2023 |
| First posted | Apr 9, 2020 |
| Last update posted | Jan 18, 2024 |
| Countries | Argentina, Australia, Canada, Chile, Denmark, Italy, Japan, Mexico, Netherlands, Poland, Russia, South Korea and 5 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: